Dementia remains the major predictor of death among octogenarians. A study of two population cohorts of 85-year-olds examined 22 years apart

Hanna Wetterberg· Jenna Najar· Lina Rydéń· Mats Ribbe· Therese Rydberg Sterner· Anna Zettergren· Xinxin Guo· Hanna Falk Erhag· Simona Sacuiu· Silke Kern· Ingmar Skoog

Received: 21 May 2020 / Accepted: 27 March 2021 / Published online: 21 April 2021 © The Author(s) 2021

Abstract
Dementia is the major predictor of death in old age. The aim of this paper was to determine whether 8-year mortality among 85-year olds with and without dementia, and if the contribution of dementia to mortality relative to other common diseases has changed. We used two population-based cohorts of 85-year-olds (N = 1065), born in 1901–02 and 1923–24, which were examined with identical methods in 1986–87 and 2008–2010 and followed for 8-year mortality according to data from the Swedish Tax Agency. Dementia was diagnosed according to DSM-III-R. Other diseases were diagnosed based on self-reports, close informant interviews, somatic examinations, and the Swedish National In-patient Register. Compared to cohort 1901–02, cohort 1923–24 had a lower 8-year mortality both among those with (HR 0.7; 95% CI 0.5–0.99) and without dementia (HR 0.7; 95% CI 0.5–0.9). Dementia was associated with increased mortality in both cohorts (cohort 1901–02, HR 2.6; 95% CI 2.0–3.2, cohort 1923–24, HR 2.8; 95% CI 2.3–3.5), and remained the major predictor of death, with a population attributable risk of 31.7% in 1986–87 and 27.7% in 2008–10. Dementia remained the most important predictor of death in both cohorts. The relative risk for mortality with dementia did not change between cohorts, despite a decreased mortality rate in the population.

Keywords  Epidemiology · Dementia · Life expectancy · Mortality · Secular trends · Cohort studies

Introduction
The increased life expectancy worldwide will result in a substantial increase in the number of individuals living with dementia, from almost 50 million today to 132 million by 2050 [1]. Dementia is one of the strongest predictors of mortality among older adults [2–4]. A number of recent studies suggest that the age-specific incidence of dementia declines in Western countries [5–10]. It is not clear whether
22 years later. The aim of this study was to examine whether 8-year mortality in relation to dementia among 85-year olds has changed. In addition, we examined the importance of dementia relative to other common diseases to predict mortality in the two cohorts.

Methods

Study population

Two cohorts of 85-year-olds from the Gothenburg H70 Birth Cohort studies, Sweden, born 1901–02 and 1923–24, were examined in 1986–87 (N = 494; response rate 64.2%) and 2008–10 (N = 571, response rate 60.5%) (Fig. 1). Both samples were systematically obtained from the Swedish Population Register based on birth dates, and included persons living in private households and in institutions. In cohort 1901–02, non-participants and participants were similar regarding sex (women 71% versus 75%), 3-year mortality rate (28.7% versus 25.9%) [22], and National Inpatient Register diagnoses for cardiovascular disorders (27.8% versus 27.7%), stroke (2.2% versus 2.5%), and depression (1.1% versus 0.8%). In cohort 1923–24, non-participants and participants were similar regarding sex (women 64.1% versus 62.9%), and National Inpatient Register diagnoses for cardiovascular disorders (35.9% versus 38.9%), stroke (8.3% versus 7.9%), and mental disorders (7.0% versus 4.2%). However, non-participants had higher 3-year mortality rate (23.3% versus 16.6%; P = 0.011), and higher prevalence of depression (3.5% versus 1.2%; P = 0.022), compared to participants [23].

The Ethics Committee for Medical Research at the University of Gothenburg approved the study and all participants, or a close relative, gave informed consent to participate according to the Declaration of Helsinki [23].

Examinations

The examinations were conducted at an outpatient clinic or in the participant’s home, and included comprehensive cognitive, psychiatric, social, somatic, and functional examinations [22].

The semi-structured neuropsychiatric examinations, performed by a psychiatrist in 1986–87 and by experienced psychiatric research nurses in 2008–10, included assessments of psychiatric symptoms, signs of dementia, tests of mental functioning (e.g. memory, proverbs, language, visuospatial...
and executive abilities, apraxia, construction, agnosia), the Mini Mental State Examination (MMSE) [24] and the Alzheimer’s Disease Assessment Scale – cognitive Subscale (ADAS-Cog) [25]. The nurses conducting the examination in 2008–10 were trained and supervised by the principal investigator (IS), who performed the examinations in 1986–87. Inter-rater reliability for signs and symptoms used to diagnose dementia was tested by dual ratings by psychiatric research nurses or psychiatrists. Inter-rater agreement varied between 89.4 and 100.0% (Kappa values 0.74–1.00) [23].

Semi-structured interviews with close informants were performed at baseline in 451 participants (91%) in 1986–87 and 443 (78%) in 2008–2010. The close informant interviews comprised questions about changes in behaviour and intellectual function (e.g. changes in personality, memory, intellectual ability, language, visuospatial function, psychiatric symptoms, activities of daily living), and background factors (e.g. history of stroke/TIA) [23].

**Diagnosis of dementia**

The diagnostic procedures were identical at both examinations, as described in detail previously [22]. First, a diagnosis of dementia was made from the psychiatric examination and the close informant interview separately using an algorithm based on the DSM-III-R criteria [26]. A final diagnosis was made from the combined information. All diagnoses were re-evaluated in 2019 to make diagnostic procedures as similar as possible. In this process, one individual born 1923–24 was no longer considered to have dementia.

The details of the classification of different etiological subgroups are described previously [27]. Alzheimer’s disease (AD) was classified according to NINCDS-ADRDA-criteria [28], vascular dementia (VAD) was diagnosed similar to NINDS-AIREN-criteria [29], mixed dementia was diagnosed when there was a history of stroke/TIA without clear temporal connection with dementia onset (more than one year), and other causes were diagnosed when other disorders of sufficient degree to produce dementia evolved in temporal connection with dementia.

**Diagnosis of other diseases**

Information about other diseases (i.e. cancer, cerebrovascular disorders, congestive heart failure, diabetes, chronic bronchitis, atrial fibrillation, angina pectoris, and myocardial infarction) was obtained through semi-structured interviews, laboratory tests, information on medications, and the National Inpatient Register. Detailed information on diagnostics are found in online resource 1.

**Other covariates**

Educational level was self-reported as compulsory education only or at least one more year.

**Information on mortality**

Information on date of death was available from the census records administrated by the Swedish Tax Agency, which records all deaths of Swedish citizens [30].

**Statistical methods**

Baseline characteristics were compared using Pearson’s Chi-square test for categorical variables, independent samples t-test for differences in means, and Mann–Whitney U Test for differences in medians. Median survival time and 95% confidence interval (CI) was derived from Kaplan–Meier survival analysis. Cox proportional hazards models were used to compare mortality between the cohorts in five models, presented as Hazard ratios (HR) and 95% confidence intervals (CI). As mean age was slightly higher in cohort 1923–24 [23], all models were adjusted for exact age. Model 1 adjusted for age and sex. Dementia was added in Model 2. Dementia severity was used instead of dementia in Model 3, as cohort 1923–24 had less mild dementia [23]. In Model 4, educational level was added. In Model 5, relevant diseases were added. To select diseases to include in Model 5, primary analyses were performed where each disease was analysed in relation to mortality, using age and sex as covariates and included in Model 5 if the P-values in the primary analyses were ≤ 0.2.

Analyses stratified by sex and dementia status were then performed using Models 1–5.

In order to investigate potential effect modification by cohort, the interaction terms (sex*cohort), (dementia status*cohort), and (education*cohort) were used.

Population attributable risk (PAR), which takes into consideration both the relative risk for mortality in individuals with the disease and the prevalence of the disease in the population, was calculated according to the formula:

\[
PAR = \frac{p(r - 1)}{[p \times r + (1 - p)]}.
\]

In this formula, p is the proportion of the population with the risk factor and r is the relative risk [31]. The relative risk was derived from the fully adjusted Cox proportional hazards model. When selecting diseases to include in the PAR analyses, the two cohorts were analysed separately.

All models met the proportional hazards assumption based on Schoenfeld residuals. Analyses were performed...
Results

Characteristics of the samples are given in Table 1, as partly reported previously [23]. Compared to cohort 1901–02, cohort 1923–24 was older, included a higher proportion of men, a higher proportion with more than compulsory education, were more often married, had a distribution of the MMSE towards higher scores, had more often a history of cerebrovascular disorders, congestive heart failure, diabetes mellitus, myocardial infarction, less often a history of atrial fibrillation, and had more often cholesterol and hypertension treatment.

Total mortality

The median survival time from baseline in cohort 1901–02 was 4.9 (95% CI 4.4–5.5) years, and in cohort 1923–24 5.7 (95% CI 5.2–6.2) years. Women had lower mortality than men both in cohort 1901–02 (HR 0.7; 95% CI 0.5–0.8) and cohort 1923–24 (HR 0.8; 95% CI 0.6–0.96).

When adjusting for sex and age (Model 1), mortality was lower in cohort 1923–24 compared to cohort 1901–02 (HR 0.6; 95% CI 0.5–0.7), both in women (HR 0.6; 95% CI 0.4–0.7) and in men (HR 0.6; 95% CI 0.4–0.9). The cohort differences remained in the total group and in women in all models. Among men, the cohort difference was no longer significant when adding education (online resource 2). The interaction terms (sex*cohort), and (education*cohort) were not significant, indicating that cohort changes in mortality did not differ by sex or education.

Mortality in relation to dementia

Mortality was higher in those with dementia compared to those without, both in cohort 1901–02 (HR 2.6; 95% CI 2.1–3.2), and in cohort 1923–24 (HR 2.9; 95% CI 2.3–3.6), when adjusting for age and sex. Compared to individuals without dementia, mortality was higher in AD (cohort 1901–02, HR 2.2; 95% CI 1.9–3.0, cohort 1923–24, HR 2.6; 95% CI 1.9–3.4), VAD (cohort

| Table 1 Characteristics of 85-year-olds in the Gothenburg Birth Cohort studies at baseline |
|-----------------------------------------------------------|-----------------|
| Cohort                                                   | 1901–02 (n = 494) | 1923–24 (n = 571) |
| Female sex % (n)                                         | 71.1 (351/494)   | 62.9 (359/571)* |
| Age at baseline, mean (SD)                               | 85.5 (0.1)       | 85.9 (0.2)***   |
| More than mandatory education % (n)                      | 24.9 (113/454)   | 56.0 (311/555)*** |
| MMSE, median (IQR) (n)                                   | 27 (22–29) (491) | 27 (24–29) (555)** |
| Married, % (n)                                           | 23.9 (117/490)   | 35.5 (195/550)*** |
| Sheltered living, % (n)                                  | 24.1 (119/494)   | 13.3 (76/561)*** |
| Dementia, % (n)                                          | 29.8 (147/494)   | 21.5 (123/571)** |
| **Dementia severity**                                    |                 |                 |
| Mild % (n)                                               | 27.9 (41/147)    | 10.6 (13/123)*** |
| Moderate % (n)                                           | 34.7 (51/147)    | 46.3 (57/123)   |
| Severe % (n)                                             | 37.4 (55/147)    | 43.1 (53/123)   |
| Cancer % (n)                                             | 7.3 (36/494)     | 9.3 (53/571)    |
| Cerebrovascular disorders % (n)                           | 18.8 (93/494)    | 24.3 (139/571)* |
| Congestive heart failure % (n)                            | 25.5 (126/494)   | 32.4 (185/571)* |
| Diabetes mellitus % (n)                                  | 9.1 (45/494)     | 14.7 (84/571)   |
| Chronic bronchitis % (n)                                 | 11.7 (58/494)    | 8.4 (48/571)    |
| Atrial fibrillation % (n)                                | 18.4 (91/494)    | 24.9 (142/571)* |
| Angina pectoris % (n)                                    | 21.9 (108/494)   | 20.0 (114/571)** |
| Myocardial infarction % (n)                              | 11.7 (58/494)    | 19.3 (110/571)  |
| Total cholesterol mmol/L, mean (SD), (n)                 | 5.4 (1.2) (425)  | 5.3 (1.2) (514) |
| Cholesterol treatment                                    | 0.0 (0/494)      | 20.1 (111/553)*** |
| Hypertension, % (n)                                      | 82.4 (406/493)   | 56.8 (300/528)*** |
| Hypertension treatment, % (n)                            | 17.5 (83/475)    | 54.9 (298/543)*** |

Statistical analysis: Pearson’s Chi-square test for categorical variables, independent samples t-test for differences in means, and Mann–Whitney U Test for differences in medians.

* P < 0.05, ** P < 0.01, *** P < 0.001, all other values are not significant
Dementia remains the major predictor of death among octogenarians. A study of two population...

1901–02, HR 3.3; 95% CI 2.3–4.7, cohort 1923–24, HR 3.5; 95% CI 2.4–5.2), and in VAD or mixed dementia (cohort 1901–02, HR 3.4; 95% CI 2.5–4.7, cohort 1923–24, HR 3.5; 95% CI 2.5–4.9).

When stratifying by dementia status, the median survival time from baseline among those without dementia in cohort 1901–02 was 6.0 (95% CI 5.5–6.5) years and in cohort 1923–24 6.5 (95% CI 6.0–7.0) years. Among those with dementia, the median survival time from baseline was 2.7 (95% CI 2.4–3.0) years in cohort 1901–02 and 3.0 (95% CI 2.5–3.5) years in cohort 1923–24. The mortality declined between cohorts among those without dementia (HR 0.7; 95% CI 0.5–0.9), but the decline was not significant among those with dementia (HR 0.7; 95% CI 0.5–1.0) (Model 1) (Fig. 2).

Mortality was related to dementia severity in both cohorts (data not shown). Adding dementia severity to the models, mortality was lower in cohort 1923–24 compared to cohort 1901–02 also among those with dementia (Model 3, online resource 2). In Model 4 (online resource 2), the cohort difference remained in those without dementia, but not in those with. In the fully adjusted model (Model 5, Table 2), mortality was lower both among those without (HR 0.7; 95% CI 0.5–0.9) and with dementia (HR 0.7; 95% CI 0.5–0.99). Similar results were observed for both sexes, but changes only reached statistical significance in dementia-free women (Table 2).

The interaction term (dementia status*cohort) was not significant, indicating that cohort changes in mortality did not differ by dementia status.

Population attributable risk (PAR) (Table 3)

Independent predictors for 8-year mortality in both cohorts were sex, dementia (cohort 1901–02 PAR 31.7%, cohort 1923–24 PAR 27.7%), cerebrovascular disorders (cohort 1901–02 PAR 5.4%, cohort 1923–24 PAR 8.0%), and myocardial infarction (cohort 1901–02 PAR 8.4%, cohort 1923–24 PAR 6.2%). Congestive heart failure was an independent predictor only in cohort 1923–24 (PAR 9.8%).

When adding dementia subgroups instead of total dementia to the model, sex, AD (PAR 1901–02 16.6%, PAR 1923–24 17.3%), VAD (PAR 1901–02 14.1%, PAR 1923–24 5.6%), mixed dementia (PAR 1901–02 9.1%, PAR 1923–24 4.2%), other dementia types (PAR 1901–02 3.3%, PAR 1923–24 8.1%), and myocardial infarction (PAR 1901–02 8.0%, PAR 1923–24 6.7%) were independent predictors for 8-year mortality both in cohort 1901–02 and 1923–24. In cohort 1923–24, cerebrovascular disorders (PAR 10.1%) and heart failure (PAR 9.8%) were also independent predictors for 8-year mortality. Results for subgroups stratified by sex can be seen in online resource 3.

Among women, independent predictors for 8-year mortality in both cohorts were dementia (PAR 1901–02 34.9%, PAR 1923–24 28.0%), and cerebrovascular disorders (PAR 1901–02 8.5%, PAR 1923–24 8.6%). In cohort 1901–02, atrial fibrillation (PAR 7.7%) and myocardial infarction (PAR 12.6%) were also independent risk factors.

Among men, independent predictors for 8-year mortality in both cohorts was dementia (PAR 1901–02 25.1%, PAR...
1923–24 (29.6%). In cohort 1901–02, chronic bronchitis (PAR 12.3%) was also an independent risk factor. In cohort 1923–24, heart failure (PAR 11.0%) and atrial fibrillation (PAR 13.4%) were also independent predictors.

**Discussion**

We aimed to examine whether 8-year mortality in relation to dementia, and whether the importance of dementia to predict mortality relative to other common diseases, changed between two representative samples of 85-year-olds from Gothenburg, Sweden, examined 22 years apart (1986–87 and 2008–10). We found that mortality decreased to a similar extent in those with and without dementia, and that dementia remained the major predictor of death with population attributable risks of 32% 1986–87 and 28% in 2008–10, despite a lower prevalence of dementia in the cohort born 1923–24.

In relation to our first aim, the finding that mortality decreased to a similar extent in individuals with and without dementia is similar to findings from the Kungsholmen Study from central Stockholm, comparing populations aged...
Dementia remains the major predictor of death among octogenarians. A study of two population examinations in 1987–89 and 2001–2004 [18]. The French PAQUID study, which compared populations aged 65 years and older examined in 1993 and 2002 [17], found that mortality decreased in both groups, but that the decrease was more pronounced in those without dementia. In contrast, the Framingham study comparing populations aged 60 years and older, examined 1977–1984 and 2004–2008, reported a higher mortality after diagnosis of incident dementia in the later cohort [21]. They suggested that the absolute number of years lived with dementia decreased over the 30-year period. In line with this, the MRC CFAS study from UK reported a compression of cognitive morbidity in women examined in 1991 and 2011, as a result of gain in years without cognitive impairment and a

Table 3  Population attributable risk for diseases predicting 8-year mortality, stratified by sex and cohort

| Disease                          | % with disease | HR (95% CI) | P-value | PAR. % | % with disease | HR (95% CI) | P-value | PAR. % |
|----------------------------------|----------------|-------------|---------|--------|----------------|-------------|---------|--------|
| **Total**                        |                |             |         |        |                |             |         |        |
| Dementia                         | 29.8           | 2.6 (2.0–3.2) | <.001   | 31.7   | 21.5           | 2.8 (2.2–3.5) | <.001   | 27.7   |
| Cerebrovascular disorders        | 18.8           | 1.3 (1.0–1.7) | .043    | 5.4    | 24.3           | 1.4 (1.1–1.7) | .009    | 8.0    |
| Myocardial infarction            | 11.7           | 1.8 (1.3–2.4) | <.001   | 8.4    | 19.3           | 1.3 (1.0–1.8) | .029    | 6.2    |
| Heart failure                    | *              |             |         |        | 32.4           | 1.3 (1.1–1.7) | .013    | 9.8    |
| AD                               | 14.4           | 2.4 (1.8–3.2) | <.001   | 16.6   | 11.6           | 2.8 (2.1–3.8) | <.001   | 17.3   |
| VAD                              | 8.7            | 2.9 (1.9–4.4) | <.001   | 14.1   | 5.1            | 2.2 (1.4–3.4) | .001    | 5.6    |
| Mixed                            | 3.6            | 3.7 (2.3–6.2) | <.001   | 9.1    | 2.3            | 2.9 (1.6–5.2) | <.001   | 4.2    |
| Other                            | 3.0            | 2.1 (1.2–3.7) | .007    | 3.3    | 2.6            | 4.4 (2.5–7.6) | <.001   | 8.1    |
| Cerebrovascular disorders        | *              |             |         |        | 24.3           | 1.5 (1.1–1.9) | .004    | 10.1   |
| Myocardial infarction            | 11.7           | 1.7 (1.3–2.4) | <.001   | 8.0    | 19.3           | 1.4 (1.1–1.8) | .020    | 6.7    |
| Heart failure                    | *              |             |         |        | 32.4           | 1.3 (1.1–1.7) | .013    | 9.8    |
| AD                               | 19.7           | 1.5 (1.1–2.0) | .014    | 8.5    | 22.0           | 1.4 (1.1–1.9) | .023    | 8.6    |
| VAD                              | 19.7           | 1.4 (1.0–2.0) | .034    | 7.7    | 7.7            | *           |         |       |
| Mixed                            | 10.8           | 2.3 (1.6–3.4) | <.001   | 12.6   | *              |             |         |       |
| Dementia                         | 30.8           | 2.8 (2.1–3.7) | <.001   | 34.9   | 23.7           | 2.6 (2.0–3.5) | <.001   | 28.0   |
| Cerebrovascular disorders        | 19.7           | 1.5 (1.1–2.0) | .014    | 8.5    | 22.0           | 1.4 (1.1–1.9) | .023    | 8.6    |
| Atrial fibrillation              | 19.7           | 1.4 (1.0–2.0) | .034    | 7.7    | 7.7            | *           |         |       |
| Myocardial infarction            | 10.8           | 2.3 (1.6–3.4) | <.001   | 12.6   | *              |             |         |       |
| AD                               | 27.3           | 2.2 (1.5–3.3) | <.001   | 25.1   | 17.9           | 3.3 (2.2–5.0) | <.001   | 29.6   |
| Chronic bronchitis               | 16.1           | 1.9 (1.2–3.1) | .012    | 12.3   | **             |             |         |       |
| Heart failure                    | *              |             |         |        | 27.4           | 1.5 (1.0–2.1) | .050    | 11.0   |
| Atrial fibrillation              | **             |             |         |        | 28.8           | 1.5 (1.1–2.2) | .027    | 13.4   |

Cox regressions models to analyse which disorders that predict 8-year mortality. Disorders that remained significant predictors (at p < 0.05) in the fully adjusted models are presented in the table. All models are adjusted for exact age

*Not significant in the fully adjusted model

**Not significantly related to mortality

aAdjusted for sex, dementia, cerebrovascular disorders, congestive heart failure, diabetes mellitus, chronic bronchitis, atrial fibrillation, and myocardial infarction

bAdjusted for sex, dementia, cerebrovascular disorders, congestive heart failure, diabetes mellitus, chronic bronchitis, atrial fibrillation, and myocardial infarction

cAdjusted for sex, AD, VAD, mixed dementia, other types of dementia, cerebrovascular disorders, congestive heart failure, diabetes mellitus, chronic bronchitis, atrial fibrillation, angina pectoris, and myocardial infarction

dAdjusted for sex, AD, VAD, mixed dementia, other types of dementia, cerebrovascular disorders, congestive heart failure, diabetes mellitus, chronic bronchitis, atrial fibrillation, angina pectoris, and myocardial infarction

eAdjusted for dementia, cerebrovascular disorders, congestive heart failure, atrial fibrillation, and myocardial infarction

fAdjusted for dementia, cerebrovascular disorders, congestive heart failure, diabetes mellitus, chronic bronchitis, atrial fibrillation, angina pectoris, and myocardial infarction

gAdjusted for dementia, cerebrovascular disorders, congestive heart failure, diabetes mellitus, chronic bronchitis, atrial fibrillation, angina pectoris, and myocardial infarction

hAdjusted for dementia, cerebrovascular disorders, congestive heart failure, atrial fibrillation, and myocardial infarction

iAdjusted for dementia, cerebrovascular disorders, congestive heart failure, diabetes mellitus, chronic bronchitis, atrial fibrillation, angina pectoris, and myocardial infarction

jAdjusted for dementia, cerebrovascular disorders, congestive heart failure, diabetes mellitus, chronic bronchitis, atrial fibrillation, angina pectoris, and myocardial infarction

kAdjusted for dementia, cerebrovascular disorders, congestive heart failure, diabetes mellitus, chronic bronchitis, atrial fibrillation, angina pectoris, and myocardial infarction
reduction in years lived with cognitive impairment [32]. The reason for discrepancies could be that these latter studies examined mortality in incident dementia, while we examined mortality in prevalent dementia. We have previously reported that the decrease in dementia prevalence was most accentuated for mild dementia [23], suggesting a more compressed disease course in later cohorts. Other explanations for discrepancies include the high age of our sample, different examination years, or differences in diagnostic criteria. More studies are needed on whether mortality decreases differently between persons with and without dementia, as this may have important implications for health care planning and future burden of dementia on society.

Explanations for the increased survival with dementia include a growing awareness that health-care interventions should be provided to patients with dementia [11], including person-centred care [11, 18, 33]. However, this does not explain why mortality decreased to a similar extent in those with and without dementia. Our finding that the excess mortality in those with dementia persisted suggests that it is not the factors affecting increased risk of mortality in dementia that have changed. Instead, the findings suggest that those with and without dementia were affected to a similar extent by factors decreasing mortality over time. The two cohorts are born 22 years apart, and their life-courses have therefore been affected by different societal contexts across historical times [34], including improvements in health care and living conditions. In addition, we have previously reported improvements in health-related factors among later born cohorts, e.g. improved lung function [14], decreased blood pressure [15], and decreased prevalence of cardiovascular disorders [16], which may have had beneficial effects on mortality. In addition, among these cohorts of 85-year olds, the prevalence of hypertension was lower and antihypertensive treatment more common in the later born cohort, while statins were not yet introduced in the 1980s. The Global Burden of Disease Study reported that while the total number of deaths from dementia increased by 40% between 2005 to 2015, an age-standardized decrease was found [35], maybe reflecting a reduced burden of cardiovascular diseases. However, neither dementia nor educational level or any of the selected somatic disorders explained the cohort difference in mortality in our study. Similarly, educational level [18, 21] and vascular factors [17] did not explain the decrease in mortality in previous studies.

In relation to our second aim, we found that dementia remained the major predictor of mortality over more than two decades. Thus, PAR for dementia was substantially higher than for any other diseases in both cohorts, and dementia predicted 32% of deaths among 85-year-olds in the 1980s and 28% of mortality in the 2010s. Similar to our findings for dementia, a MRC CFAS study reported that the relationship between frailty and mortality remained stable across cohorts [36], in contrast to a previous study from our group, where frailty was related to lower mortality in a later-born cohort [37]. Interestingly, the gender gap in PAR for dementia decreased from cohort 1901–02 (25% in men and 35% in women) to cohort 1923–24 (30% in men and 28% in women). Cerebrovascular disorders and myocardial infarction predicted mortality in both cohorts, with PARs ranging from 5–8%. In a previous study on 95-year-olds, PAR for dementia in relation to mortality was 30% in men and 44% in women, suggesting that the effect of dementia on mortality increases with age, at least among women [38]. The prevalence of dementia have a major impact on mortality rates, which has important public health implications [4]. More studies are therefore needed on the relative importance of dementia on overall mortality.

The increased mortality in dementia is well-established [2, 12, 19, 20, 38, 39], but the reasons are not clear. Possible explanations include that brain control systems which are vital for survival, such as regulation of cardiac function, blood pressure, appetite, and energy balance [40, 41] might be affected by the pathologic processes of dementia [38]. Another reason may be that the detection rate of other diseases is lower among individuals with dementia compared to their aged peers [42].

Our results showed that mortality has decreased in both men and women, and we found no interaction between sex and cohort in relation to mortality, indicating no sex difference in the decrease. This is in contrast to the view that decline in mortality has been steeper among men, resulting in a decreased gender gap in life expectancy [43, 44]. However, results from previous studies show varying patterns. Mortality among individuals above age 85 in the MRC CFAS study decreased more in women than among men [32], but in the Kungsholmen study mortality decreased similarly in men and women [18]. Among those with dementia, a declining mortality was only observed in women in Kungsholmen and PAQUID [17, 18]. Whether sex differences in risk factors for dementia, such as vascular factors [45] and depression [46] contribute to sex differences in mortality among individuals with dementia remains unclear.

Among the strengths of our study are identical methods and diagnoses in two population-based samples of 85-year-olds examined two decades apart. Further, dementia diagnoses were based on information from both neuropsychiatric examinations and close informant interviews, and all participants were examined for dementia without screening. In addition, we derived date of death from the Swedish Tax agency, which records all deaths of Swedish citizens [30]. There are also some possible limitations. First, the relatively small sample sizes might affect the power of the analyses, especially when stratifying by sex and dementia status. Second, the response rate ranged from 60 to 63%, which is satisfactory in this age group, but we
Dementia remains the major predictor of death among octogenarians. A study of two population...

cannot exclude the possibility that response rates among those with dementia have changed, or that characteristics of non-responders differ between cohorts. Third, three-year mortality rate was higher among non-responders in cohort 1923–24, while no such difference was observed in cohort 1901–02. This could have accentuated differences in mortality between cohorts. Fourth, more participants agreed to close informant interviews in cohort 1901–02 compared to 1923–24. It is possible that this led to fewer identified cases of dementia in the latter cohort. Fifth, cohort 1923–24 was slightly older than cohort 1901–02 due to a delayed study start of a few months. The study on the cohort born 1923–24 also took longer time to complete than the study on the cohort born 1901–02 (648 versus 504 days). We have therefore adjusted for exact age in all models. Sixth, information on covariates are based on self-report and the National Inpatient Register, which could have been affected by changes in awareness of diseases. In addition, previous studies have shown that some diseases are under-diagnosed among individuals with dementia [47]. This could potentially affect PAR in our study. In conclusion, we found that mortality among 85-year-olds born 22 years apart declined to a similar degree among those with and without dementia. Dementia remained the most important predictor of death in both cohorts. The relative risk for mortality with dementia did not change between cohorts, despite a decreased mortality rate in the population. The reasons behind the high mortality rate in dementia needs to be further elucidated in future studies.

Supplementary Information The online version contains supplementary material available at https://doi.org/10.1007/s10654-021-00745-5.

Author contributions Wetterberg and Skoog had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Concept and design: Wetterberg, Skoog. Acquisition, analysis or interpretation of data: All authors. Drafting of the manuscript Wetterberg and Skoog. Statistical analysis: Wetterberg. Critical revision of the manuscript for important intellectual content: All authors.

The authors would like to thank all participants of the H70 studies in Gothenburg, and the members of the research group for their cooperation in data collection and management, and acknowledge Dr. Svante Östling, who contributed to this work but passed away before the paper was finalized.

Funding Open access funding provided by University of Gothenburg. The study was financed by grants from the Swedish state under the agreement between the Swedish government and the county councils, the ALF-agreement (ALF 716681), The Swedish Research Council (2007–7462, 2012–5041, 2015–02830, 2019–01096, 2013–8717, 2017–00639), Swedish Research Council for Health, Working Life and Welfare (2006–0596, 2008–1111, 2010–0870, 2013–1202, AGECAP 2013–2300, 2013–2496, 2013–0475), Konung Gustaf V:s och Drottning Victorias Frimurarestiftelser, Hjärnfonden (FO2014–0207, FO2016–0214, FO2018–0214, FO2019–0163), Alzheimerfonden (AF-554461, AF-647651, AF-743701, AF-844671, AF-930868), Eivind och Elsa K:son Sylvans stiftelse, The Alzheimer’s Association Zenith Award (ZEN-01–3151), The Alzheimer’s Association (IIRG-09–131338), Anna-Lisa och Bror Björnssons stiftelse, and Stiftelsen Handlanden Hjalmar Svenssons forskningsfond (HJSV20190229).

Availability of data and material The datasets generated during and analyzed during the current study are available from the corresponding author on reasonable request, and according to regulations of the General Data Protection Regulation.

Code availability Not applicable.

Declarations

Conflicts of interest I.S. have been consultant for Takeda and given payed lectures for Takeda in relation to vascular dementia. None of the other authors has had competing financial interests in relation to this manuscript.

Ethics approval All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The H70 study was approved by the Regional Ethical Review Board in Gothenburg (approval numbers: 52/76, 607–08).

Consent to participate Informed consent was obtained from all individual participants included in the study. In cases of dementia, where informed consent could not be fully informed, informed consent was also obtained from a close relative. No examination was performed, if the person with dementia refused participation.

Consent for publication Not applicable.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Alzheimer Disease International. World Alzheimer report. London: Alzheimer Disease International; 2015.
2. Tschanz JT, Corcoran C, Skoog I, Khachaturian AS, Herrick J, Hayden KM, et al. Dementia: the leading predictor of death in a defined elderly population: the Cache County Study. Neurology. 2004;62(7):1156–62.
3. Guehne U, Riedel-Heller S, Angermeyer MC. Mortality in Dementia. Neuroepidemiology. 2005;25(3):153–62. https://doi.org/10.1159/000086680.
4. Aervarsson O, Svanborg A, Skoog I. Seven-year survival rate after age 85 years: relation to Alzheimer disease and vascular dementia. Arch Neurol. 1998;55(9):1226–32.
5. Grasset L, Brayne C, Joly P, Jacqumin-Gadda H, Peres K, Foubert-Samier A, et al. Trends in dementia incidence: Evolution over a 10-year period in France. Alzheimers Dement. 2016;12(3):272–80. https://doi.org/10.1016/j.jalz.2015.11.001.

6. Matthews FE, Stephan BC, Robinson L, Jagger C, Barnes LE, Arthur A, et al. A two decade dementia incidence comparison from the cognitive function and ageing studies I and II. Nat Commun. 2016;7:11398. https://doi.org/10.1038/ncomms11398.

7. Satizabal CL, Beiser AS, Chouraki V, Chene G, Dufouil C, Seshadri S. Incidence of dementia over three decades in the framingham heart study. N Engl J Med. 2016;374(6):523–32. https://doi.org/10.1056/NEJMoa1504327.

8. Schrijvers EM, Verhaaren BF, Hofman A, Ikram MA, Breteler MM. Is dementia incidence declining? Trends in dementia incidence since 1990 in the Rotterdam study. Neurology. 2012;78:1456–63. https://doi.org/10.1212/WNL.0b013e3182553be6.

9. Wu YT, Fratiglioni L, Matthews FE, Lobo A, Breteler MM, Skoog I, et al. Dementia in western Europe: epidemiological evidence and implications for policy making. Lancet Neurol. 2016;15(1):116–24. https://doi.org/10.1016/S1474-4422(15)00092-7.

10. Wu YT, Beiser AS, Breteler MM, Fratiglioni L, Helmer C, Hendrie HC, et al. The changing prevalence and incidence of dementia over time—current evidence. Nat Rev Neurol. 2017;13:327. https://doi.org/10.1038/nrneurol.2017.63.

11. Prince M, Ali GC, Guerchet M, Prina AM, Peres K, Joly P, Sabathe C, Foubert-Samier A, Dartigues JF, et al. Secular trends of mortality and dementia-free life expectancy over a 10-year period in France. Alzheimers Dement. 2016;12(3):272–80. https://doi.org/10.1016/j.jalz.2015.11.001.

12. Todd S, Barr S, Roberts M, Passmore AP. Survival in dementia and predictors of mortality: a review. Int J Geriatr Psychiatry. 2013;28(11):1109–24.

13. Beeri MS, Goldbourt U. Late-life dementia predicts mortality beyond established midlife risk factors. Am J Geriatr Psychiatry. 1993;1:134–51.

14. Lak VW, Skoog I, Guo X. Secular trends in lung function and its relation to survival in Swedish 75 year olds 1976–2006. Age Ageing. 2012;41(6):735–40. https://doi.org/10.1093/ageing/afs098.

15. Zhi X, Joas E, Waern M, Ostling S, Borjesson-Hanson A, Skoog I, et al. Decreasing prevalence of dementia in 85-year olds examined 22 years apart: the influence of education and stroke. Sci Rep. 2017;7(1):6136. https://doi.org/10.1038/s41598-017-05022-8.

16. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRSA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s disease. Neurology. 1984;34(7):939–44.

17. Roman GC, Tatemichi TK, Erkinjuntti T, Cummings JL, Masdeu JC, Garcia JH et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology. 1993;43(2):250–60.

18. Brooke HL, Talback M, Hornblad J, Johansson LA, Ludvigsson JD, Björklund P, et al. The Swedish cause of death register. Eur J Epidemiol. 2015;30(9):765–73. https://doi.org/10.1007/s10654-015-0316-1.

19. Henneman CH, Buring JE, Sherry L, Mayrent. Epidemiology in medicine. Boston: Little, Brown; 1987.

20. Jagger C, Matthews FE, Wohland P, Fouweather T, Stephan BC, Robinson L, et al. A comparison of health expectancies over two decades in England: results of the cognitive function and ageing study I and II. Lancet. 2016;387(10020):779–86. https://doi.org/10.1016/S0140-6736(15)00497-2.

21. Garcia-Ptacek S, Farahmand B, Karelinti O, Religa D, Cuadrado ML, Eriksdotter M. Mortality risk after dementia diagnosis by dementia type and underlying factors: a cohort of 15,209 Patients based on the Swedish Dementia Registry. J Alzheimers Dis. 2014;41(2):467–77.

22. Skoog I. Dementia: incidence—the times, they are a-changing. Nat Rev Neurol. 2016;12(6):316–8. https://doi.org/10.1038/nrneurol.2016.55.

23. Wang H, Nagarvi M, Allen C, Barber RM, Bhutta ZA, Carter A, et al. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015. The Lancet. 2016;388(10053):1459–544. https://doi.org/10.1016/S0140-6736(16)31012-1.

24. Mousa A, Savva GM, Mintziki A, Rockwood K, Jagger C, Brayne C, et al. Is frailty a stable predictor of mortality across time? evidence from the cognitive function and ageing studies. Age Ageing. 2018;47(5):721–7. https://doi.org/10.1093/ageing/afy077.
Dementia remains the major predictor of death among octogenarians. A study of two population…

37. Backman K, Joas E, Falk H, Minnitski A, Rockwood K, Skoog I. Changes in the lethality of frailty over 30 years: evidence from two cohorts of 70-year-olds in Gothenburg Sweden. J Gerontol A Biol Sci Med Sci. 2017;72(7):945–50. https://doi.org/10.1093/gerona/glw160.

38. Borjesson-Hanson A, Gustafson D, Skoog I. Five-year mortality in relation to dementia and cognitive function in 95-year-olds. Neurology. 2007;69(22):2069–75.

39. Roehr S, Luck T, Bickel H, Brettschneider C, Ernst A, Fuchs A, et al. Mortality in incident dementia—results from the German study on aging, cognition, and dementia in primary care patients. Acta Psychiatr Scand. 2015;132(4):257–69. https://doi.org/10.1111/acps.12454.

40. McKinley MJ, Gerstberger R, Mathai ML, Oldfield BJ, Schmid H. The lamina terminalis and its role in fluid and electrolyte homeostasis. J Clin Neurosci. 1999;6(4):289–301. https://doi.org/10.1054/jocn.1998.0056.

41. Tabarean I, Morrison B, Marcondes MC, Bartfai T, Conti B. Hypothalamic and dietary control of temperature-mediated longevity. Ageing Res Rev. 2010;9(1):41–50. https://doi.org/10.1016/j.arr.2009.07.004.

42. Villarejo A, Benito-Leon J, Trincado R, Posada IJ, Puertas-Martín V, Boix R, et al. Dementia-Associated Mortality at Thirteen Years in the NEDICES Cohort Study. J Alzheimers Dis. 2011;26(3):543–51. https://doi.org/10.3233/Jad-2011-110443.

43. Rosella LC, Calzavara A, Frank JW, Fitzpatrick T, Donnelly PD, Henry D. Narrowing mortality gap between men and women over two decades: a registry-based study in Ontario Canada. BMJ Open. 2016;6(11):e012564. https://doi.org/10.1136/bmjopen-2016-012564.

44. Sundberg L, Agahi N, Fritzell J, Fors S. Why is the gender gap in life expectancy decreasing? The impact of age- and cause-specific mortality in Sweden 1997–2014. Int J Public Health. 2018;63(6):673–81. https://doi.org/10.1007/s00038-018-1097-3.

45. Gannon OJ, Robison LS, Custozzo AJ, Zuloaga KL. Sex differences in risk factors for vascular contributions to cognitive impairment and dementia. Neurochem Int. 2019;127:38–55. https://doi.org/10.1016/j.neuint.2018.11.014.

46. Underwood EA, Davidson HP, Azam AB, Tierney MC. Sex differences in depression as a risk factor for Alzheimer’s disease: a systematic review. Innov Aging. 2019;3(2):igz015. https://doi.org/10.1093/geroni/igz015.

47. Attner B, Lithman T, Noreen D, Olsson H. Low cancer rates among patients with dementia in a population-based register study in Sweden. Dement Geriatr Cogn Disord. 2010;30(1):39–42. https://doi.org/10.1159/000315509.

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.